Determination of the outcomes of pathogenetic therapy in patients with SARS-CoV-2-associated pneumonia

Etiotropic medicines used at the beginning of the pandemic have not shown their effectiveness in reducing the duration of treatment, the development of death, as well as preventing the transition to the use of mechanical ventilation. To test a new method of etiotropic and pathogenetic therapy, we analyzed the outcomes of complex therapy of 30 patients with SARS-CoV-2-associated pneumonia who were treated in the 1st clinic (advanced therapy for doctors) according to CT studies and indicators of acute phase proteins (C-reаctive protein). All patients on admission, then on the 10th day of stay in the clinic and 60 days after discharge underwent computed tomography of the chest organs in order to assess the presence of infiltration and assess the dynamics, and they measured the level of CRP at the time of admission and upon discharge from the clinic. Patients who did not have resolution according to the X-ray examination data on the 10th day, in addition to standard therapy (in accordance with the Interim Guidelines 4 version), were prescribed methylprednisolone 20 mg per day. As a result, 2 comparison groups were formed: group 1 – patients who received, in addition to standard therapy, oral glucocorticosteroids, and group 2 – who received only standard therapy. According to the study, the use of oral glucocorticosteroids (methylprednisolone 20 mg/day) in addition to standard therapy did not show their effectiveness in the treatment of SARS-CoV-2-associated pneumonia, which indicates the absence of a therapeutic effect of the drug at the selected dosage. Thus, determining the most effective treatment methods is a priority for further research.